Willette Robert N, Bao Weike, Nerurkar Sandhya, Yue Tian-Li, Doe Chris P, Stankus Gerald, Turner Gregory H, Ju Haisong, Thomas Heath, Fishman Cindy E, Sulpizio Anthony, Behm David J, Hoffman Sandra, Lin Zuojun, Lozinskaya Irina, Casillas Linda N, Lin Min, Trout Robert E Lee, Votta Bartholomew J, Thorneloe Kevin, Lashinger Erin S R, Figueroa David J, Marquis Robert, Xu Xiaoping
Investigative and Cardiac Biology, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, UW2510, King of Prussia, PA 19406, USA.
J Pharmacol Exp Ther. 2008 Aug;326(2):443-52. doi: 10.1124/jpet.107.134551. Epub 2008 May 22.
The transient receptor potential (TRP) vanilloid subtype 4 (V4) is a nonselective cation channel that exhibits polymodal activation and is expressed in the endothelium, where it contributes to intracellular Ca2+ homeostasis and regulation of cell volume. The purpose of the present study was to evaluate the systemic cardiovascular effects of GSK1016790A, a novel TRPV4 activator, and to examine its mechanism of action. In three species (mouse, rat, and dog), the i.v. administration of GSK1016790A induced a dose-dependent reduction in blood pressure, followed by profound circulatory collapse. In contrast, GSK1016790A had no acute cardiovascular effects in the TRPV4-/- null mouse. Hemodynamic analyses in the dog and rat demonstrate a profound reduction in cardiac output. However, GSK1016790A had no effect on rate or contractility in the isolated, buffer-perfused rat heart, and it produced potent endothelial-dependent relaxation of rodent-isolated vascular ring segments that were abolished by nitric-oxide synthase (NOS) inhibition (N-nitro-L-arginine methyl ester; L-NAME), ruthenium red, and endothelial NOS (eNOS) gene deletion. However, the in vivo circulatory collapse was not altered by NOS inhibition (L-NAME) or eNOS gene deletion but was associated with (concentration and time appropriate) profound vascular leakage and tissue hemorrhage in the lung, intestine, and kidney. TRPV4 immunoreactivity was localized in the endothelium and epithelium in the affected organs. GSK1016790A potently induced rapid electrophysiological and morphological changes (retraction/condensation) in cultured endothelial cells. In summary, inappropriate activation of TRPV4 produces acute circulatory collapse associated with endothelial activation/injury and failure of the pulmonary microvascular permeability barrier. It will be important to determine the role of TRPV4 in disorders associated with edema and microvascular congestion.
瞬时受体电位(TRP)香草酸亚型4(V4)是一种非选择性阳离子通道,具有多模式激活特性,在内皮细胞中表达,有助于细胞内钙离子稳态和细胞体积调节。本研究的目的是评估新型TRPV4激活剂GSK1016790A对全身心血管系统的影响,并研究其作用机制。在三种动物(小鼠、大鼠和狗)中,静脉注射GSK1016790A可导致血压呈剂量依赖性降低,随后出现严重的循环衰竭。相比之下,GSK1016790A对TRPV4基因敲除小鼠没有急性心血管作用。对狗和大鼠的血流动力学分析表明心输出量显著降低。然而,GSK1016790A对离体缓冲灌注的大鼠心脏的心率或收缩力没有影响,它能使啮齿动物离体血管环段产生强烈的内皮依赖性舒张,而一氧化氮合酶(NOS)抑制(N-硝基-L-精氨酸甲酯;L-NAME)、钌红和内皮型NOS(eNOS)基因缺失可消除这种舒张作用。然而,体内循环衰竭并未因NOS抑制(L-NAME)或eNOS基因缺失而改变,而是与肺、肠和肾中(浓度和时间合适)严重的血管渗漏和组织出血有关。TRPV4免疫反应性定位于受影响器官的内皮和上皮细胞中。GSK1016790A能在培养的内皮细胞中强烈诱导快速的电生理和形态学变化(回缩/凝聚)。总之,TRPV4的不适当激活会导致急性循环衰竭,与内皮激活/损伤和肺微血管通透性屏障功能障碍有关。确定TRPV4在与水肿和微血管充血相关的疾病中的作用将很重要。